I-Mab: Sudden Pivot To Gastric Cancer Med Still Underappreciated By Market (NASDAQ:IMAB)

I-Mab has pivoted to focus on givastomig for gastric cancer after divesting its original China portfolio and revamping leadership. Find out why IMAB is a Buy.